Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher D Hart

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Breast (Edinburgh, Scotland)|March 30, 2016
Relative benefits of newer adjuvant chemotherapy regimens in luminal breast cancer subtypesChristopher D Hart, Angelo Di Leo
Oncotargets and Therapy|January 16, 2013
Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancerChristopher D Hart, Richard H De Boer
Advances in Experimental Medicine and Biology|March 19, 2016
Metabolomics in Breast Cancer: Current Status and PerspectivesChristopher D Hart, Leonardo Tenori, Claudio Luchinat, et al.
BMC Medicine|April 11, 2015
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancersIlenia Migliaccio, Luca Malorni, Christopher D Hart, et al.
Breast (Edinburgh, Scotland)|September 1, 2015
Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypesChristopher D Hart, Giuseppina Sanna, Olimpia Siclari, et al.
Nature Reviews. Clinical Oncology|May 27, 2015
Challenges in the management of advanced, ER-positive, HER2-negative breast cancerChristopher D Hart, Ilenia Migliaccio, Luca Malorni, et al.
Pharmacological Research|February 28, 2016
Using CTCs for pharmacogenomic analysisChristopher D Hart, Francesca Galardi, Marta Pestrin, et al.
Oncotarget|September 17, 2016
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancerLuca Malorni, Silvano Piazza, Yari Ciani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2017
Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter PopulationChristopher D Hart, Alessia Vignoli, Leonardo Tenori, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2017
Quality indicators in breast cancer care: An update from the EUSOMA working groupLaura Biganzoli, Lorenza Marotti, Christopher D Hart, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Breast (Edinburgh, Scotland)|March 30, 2016
Relative benefits of newer adjuvant chemotherapy regimens in luminal breast cancer subtypesChristopher D Hart, Angelo Di Leo
Oncotargets and Therapy|January 16, 2013
Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancerChristopher D Hart, Richard H De Boer
Advances in Experimental Medicine and Biology|March 19, 2016
Metabolomics in Breast Cancer: Current Status and PerspectivesChristopher D Hart, Leonardo Tenori, Claudio Luchinat, et al.
BMC Medicine|April 11, 2015
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancersIlenia Migliaccio, Luca Malorni, Christopher D Hart, et al.
Breast (Edinburgh, Scotland)|September 1, 2015
Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypesChristopher D Hart, Giuseppina Sanna, Olimpia Siclari, et al.
Nature Reviews. Clinical Oncology|May 27, 2015
Challenges in the management of advanced, ER-positive, HER2-negative breast cancerChristopher D Hart, Ilenia Migliaccio, Luca Malorni, et al.
Pharmacological Research|February 28, 2016
Using CTCs for pharmacogenomic analysisChristopher D Hart, Francesca Galardi, Marta Pestrin, et al.
Oncotarget|September 17, 2016
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancerLuca Malorni, Silvano Piazza, Yari Ciani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2017
Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter PopulationChristopher D Hart, Alessia Vignoli, Leonardo Tenori, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2017
Quality indicators in breast cancer care: An update from the EUSOMA working groupLaura Biganzoli, Lorenza Marotti, Christopher D Hart, et al.
Pageof 2